BioSpace News Archive

Man with medical or hygienic mask standing over dead covid 19 or Corona virus raised their hand to win the Covic-19 or Coronavirus, At last mankind will win and survive over the virus concept

Editorial

The Shape of a Pandemic: Boom, Bust and Recover

As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as individuals—will never be the same again.

March 11, 2025

·

6 min read

·

Jef Akst

Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration

Mergers & acquisitions

BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

March 11, 2025

·

3 min read

·

Tristan Manalac

2D illustration showing scientists' hands editing a DNA strand

Gene editing

Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD

BEAM-302 “has set the bar for efficacy in this space,” William Blair analysts wrote in an investor note on Monday.

March 11, 2025

·

2 min read

·

Tristan Manalac

Dollar banknote cut into pieces on a yellow background

Gene therapy

Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit

Roche acquired Spark Therapeutics in 2019 for $4.8 billion.

March 11, 2025

·

2 min read

·

Tristan Manalac

Collage showing workspace concept with person’s hands at computer, a globe and a clock

Editorial

Return-to-Office Movement Should Give Life Sciences Employers Pause

While there are benefits of having employees on-site, the limited workplace flexibility at some companies following the COVID-19 pandemic can affect not only employees but also organizations’ retention and attraction efforts.

March 11, 2025

·

4 min read

·

Angela Gabriel

Pictured: Entrance to Pfizer's office in Belgium

Breast cancer

Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ stock took a 43% tumble on the news, and analysts are downcast on the drug’s prospects.

March 11, 2025

·

2 min read

·

Tristan Manalac